Drugs Made In America Acquisition II Corp. (DMII)
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
Sector: Blank Checks
Industry: Financial - Conglomerates
Drugs Made In America Acquisition II Corp. Ordinary Shares
NASDAQ:DMIIFinancial Services · Financial - Conglomerates
+0.00%$10.19
AH Close$10.19+0.00%vs close
AH Close$10.19+0.00%vs close
Mkt Cap$649.1M
Float60.34M
O/S63.7M
Inst Own71.4%
SI0.2%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income$4.19M
Total Assets$504.96M
Free Cash Flow-$1.02M
Debt & Equity
Equity 100%
Total Debt$0
Total Equity$487.16M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in DMII's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$504.96M
Liabilities$17.8M
Accounts Receivable$0
Accounts Payable$99K
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 |
|---|---|---|
| Currency | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 |
| Revenue | $0 | $0 |
| YoY Growth | - | - |
| Cost of Revenue | $0 | $0 |
| Gross Profit | $0 | $0 |
| Gross Margin | - | - |
| Research and Development | $0 | $0 |
| Selling, General, and Administrative | $1.3M | $152K |
| Other | $0 | $0 |
| Total Operating Expenses | $1.3M | $152K |
| Operating Income (EBIT) | -$1.3M | -$152K |
| Operating Margin | - | - |
| Interest Expense | $0 | $0 |
| Interest Income | $4.93M | $0 |
| Other Income (Expense) | $5.49M | $0 |
| Income Before Tax (EBT) | $4.19M | -$152K |
| Income Tax Expense | $0 | $0 |
| Net Income | $4.19M | -$152K |
| Net Income Margin | - | - |
| Supplementary Data | ||
| EPS | 0.07 | -0.00 |
| Diluted EPS | 0.07 | -0.00 |
| Weighted Average OS | 64.38M | 63.70M |
| EBITDA | -$1.3M | -$152K |
| EBITDA Margin | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 |
|---|---|---|
| Currency | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 |
| Assets | ||
| Current Assets | ||
| Cash and Cash Equivalents | $223 | $17K |
| Short-Term Investments | $0 | $0 |
| Cash and Short-Term Investments | $223 | $17K |
| Accounts Receivable | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current Assets | $0 | $0 |
| Total Current Assets | $26K | $60K |
| Long-Term Assets | ||
| Property, Plant & Equipment Net | $0 | $0 |
| Goodwill | $0 | $0 |
| Intangible Assets | $0 | $0 |
| Long-Term Investments | $504.93M | $0 |
| Deferred Tax Assets | $0 | $0 |
| Other Long-Term Assets | $0 | $78K |
| Total Long-Term Assets | $504.93M | $78K |
| Other Assets | $0 | $0 |
| Total Assets | $504.96M | $138K |
| Liabilities | ||
| Current Liabilities | ||
| Accounts Payable | $99K | $0 |
| Short-Term Debt | $0 | $250K |
| Current Income Tax Payable | $0 | $0 |
| Current Unearned Revenue | $0 | $0 |
| Other Current Liabilities | $202K | $5K |
| Total Current Liabilities | $301K | $255K |
| Long-Term Liabilities | ||
| Long-Term Debt | $0 | $0 |
| Long-Term Unearned Revenue | $17.5M | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 |
| Total Long-Term Liabilities | $17.5M | $0 |
| Other Liabilities | $0 | $0 |
| Total Liabilities | $17.8M | $255K |
| Stockholders' Equity | ||
| Preferred Stock | $0 | $0 |
| Common Stock | $504.94M | $1K |
| Retained Earnings | -$17.78M | -$152K |
| Comprehensive Income & Other | $0 | $0 |
| Other Stockholders' Equity | $0 | $34K |
| Total Equity | $487.16M | -$117K |
| Minority Interest | $0 | $0 |
| Total Liabilities and Equity | $504.96M | $138K |
| Supplementary Data | ||
| Total Debt | $0 | $250K |
| Net Debt | -$223 | $233K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 |
|---|---|---|
| Currency | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 |
| Operating Activities | ||
| Net Income | $4.19M | -$152K |
| Depreciation & Amortization | $0 | $0 |
| Deferred Income Tax | $0 | $0 |
| Stock-Based Compensation | $0 | $0 |
| Changes in Working Capital: | ||
| Accounts Receivable | -$812K | $0 |
| Inventory | $0 | $0 |
| Accounts Payable | $99K | $0 |
| Other Working Capital | $105K | -$43K |
| Total Working Capital Change | -$608K | -$43K |
| Other Non-Cash Items | -$4.6M | $0 |
| Net Cash from Operating | -$1.02M | -$194K |
| Investing Activities | ||
| Capital Expenditures | $0 | $0 |
| Acquisitions | $0 | $0 |
| Purchases of Investments | -$500M | $0 |
| Sales of Investments | $0 | $0 |
| Other Investing Activities | $0 | $0 |
| Net Cash from Investing | -$500M | $0 |
| Financing Activities | ||
| Debt Repaid | - | - |
| Common Stock Issuance | $501.54M | -$39K |
| Common Stock Repurchases | $0 | $0 |
| Dividends Paid | $0 | $0 |
| Other Financing Activities | $0 | $0 |
| Net Cash from Financing | $501M | $211K |
| Forex Effect | $0 | $0 |
| Net Change in Cash | -$17K | $17K |
| Supplementary Data | ||
| Operating Cash Flow | -$1.02M | -$194K |
| Capital Expenditure | $0 | $0 |
| Free Cash Flow | -$1.02M | -$194K |
| Cash at Beginning | $17K | $0 |
| Cash at End | $223 | $17K |